<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932252</url>
  </required_header>
  <id_info>
    <org_study_id>AS101</org_study_id>
    <nct_id>NCT04932252</nct_id>
  </id_info>
  <brief_title>A Study of A4368 in Healthy Subjects</brief_title>
  <acronym>A4368</acronym>
  <official_title>A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximal Tolerable Dose and to Evaluate the Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Doses of A4368 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autophagy Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autophagy Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A4368 is the autophagy activator that is being developed for the treatment of nonalcoholic&#xD;
      steatohepatitis.&#xD;
&#xD;
      The goal of the study is to assess the safety, tolerability, and pharmacokinetics in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The number of subjects with adverse events and abnormal laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of A4368</measure>
    <time_frame>From pre-dose to 48 hours post-dose</time_frame>
    <description>The pharmacokinetics of A4368 in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Health Subjects</condition>
  <arm_group>
    <arm_group_label>A4368 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of A4368 or placebo tablet, orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 1 repeated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4368 - Dose 2 repeated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A4368 or placebo tablet</intervention_name>
    <description>orally administered</description>
    <arm_group_label>A4368 - Dose 1</arm_group_label>
    <arm_group_label>A4368 - Dose 1 repeated</arm_group_label>
    <arm_group_label>A4368 - Dose 2</arm_group_label>
    <arm_group_label>A4368 - Dose 2 repeated</arm_group_label>
    <arm_group_label>A4368 - Dose 3</arm_group_label>
    <arm_group_label>A4368 - Dose 4</arm_group_label>
    <arm_group_label>A4368 - Dose 5</arm_group_label>
    <arm_group_label>A4368 - Dose 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female subjects&#xD;
&#xD;
          2. Subject with a body weight of ≥ 55.0 kg and within an ideal body weight ± 20%&#xD;
&#xD;
          3. Consent to follow the contraceptive guidance during the treatment period and for at&#xD;
             least 3 months after the last dose of study drug&#xD;
&#xD;
          4. Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of or current clinically significant medical illness&#xD;
&#xD;
          2. History of or current gastrointestinal disease or surgery that can influence in&#xD;
             pharmacokinetics of study drug&#xD;
&#xD;
          3. Clinically significant history of hypersensitivity to study drug or any of the&#xD;
             excipients of study drug&#xD;
&#xD;
          4. Pregnant or lactating woman&#xD;
&#xD;
          5. Clinically significant abnormal laboratory values for hematology, clinical chemistry,&#xD;
             or urinalysis&#xD;
&#xD;
          6. Clinically significant abnormal physical examination, vital signs, or 12-lead ECG&#xD;
&#xD;
          7. Heavy alcohol or caffeine intake or heavy smoker&#xD;
&#xD;
          8. Use of study drug in concurrent interventional study within 180 days prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          9. Use of any drug that may affect drug metabolic enzymes within 30 days prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
         10. Donation of whole blood within 60 days or apheresis within 30 days prior to the first&#xD;
             dose of study drug&#xD;
&#xD;
         11. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 14 days prior to the first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seunghoon Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inhyang Kim</last_name>
    <phone>+82221357957</phone>
    <email>ihkim@autophagysci.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

